Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 1/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.48 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3813504 | 0.97 | KCNE1 (0.48) | KCNE1KCNA5KCNQ1KCND3NAMPT | |
| SCHEMBL1378308 | 0.95 | KCNE1 (0.51) | KCNE1KCNA5KCNQ1KCND3NAMPT | |
| SCHEMBL3811556 | 0.91 | KCNA5 (0.44) | KCNE1KCNA5KCNQ1KCND3NAMPT | |
| SCHEMBL3893788 | 0.90 | KCNE1 (0.43) | KCNE1KCNA5KCNQ1KCND3NAMPT | |
| SCHEMBL3898299 | 0.90 | KCNE1 (0.63) | KCNE1KCNA5KCNQ1KCND3NAMPT | |
| SCHEMBL3898287 | 0.85 | POLB (0.41) | RAB9AMAPK1CYP1A2CYP2C19METAP1 | |
| SCHEMBL1379149 | 0.83 | KCNE1 (0.55) | KCNE1KCNA5KCNQ1KCND3CYP3A4 | |
| SCHEMBL1377525 | 0.79 | KCNE1 (0.51) | KCNE1KCNA5KCNQ1KCND3RAB9A | |
| SCHEMBL1380823 | 0.78 | KCNA5 (0.57) | KCNE1KCNA5KCNQ1KCND3CYP3A4 | |
| SCHEMBL3886897 | 0.78 | KCNA5 (0.54) | KCNE1KCNA5KCNQ1KCND3NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776355-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-06-12 | — | — | EP | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20060030595-A1 | (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias | MERCK SHARP & DOHME LLC | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030595-A1 | (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias | KCNN2, KCNJ2, KCNH2 | KCNE1 9/4885KCNA5 14/4885KCNQ1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.